Eikon Therapeutics filed to go public after raising more than $1 billion in private capital since 2019. The company, led by former Merck executives including Roger Perlmutter and Roy Baynes, said four candidates are in human testing — the lead program EIK1001 is in Phase 2/3 for advanced melanoma with an interim readout expected later this year per the IPO filing. Eikon was built around a Nobel Prize-linked technology that maps protein motion inside cells and has supplemented its pipeline through licensing deals, notably in toll-like receptor and PARP inhibitor programs. The filing underscores renewed appetite for select biotech IPOs after a cautious public-market window in 2024–25.